STOCKHOLM, Feb. 9, 2018 /PRNewswire/ --Fourth
Quarter
- Revenue increased by 15.2% to €152.7m (€132.5m). Organic
revenue grew by 12.6%.
- Operating profit amounted to €7.8m (€3.9m), representing an
operating margin of 5.1% (2.9%).
- Net profit amounted to €9.2m (€1.7m), which represents a net
profit margin of 6.0% (1.3%).
- Cash flow from operating activities amounted to €17.3m
(€7.3m).
- Basic/diluted earnings per share (EPS) was €0.067
(€0.008).
- EBITDA increased by 28.1% to €14.6m (€11.4m), corresponding to
an EBITDA margin of 9.6% (8.6%).
Full Year
- Revenue increased by 16.7% to €580.2m (€497.3m). Organic
revenue grew by 14.5%.
- Net profit amounted to €20.2m (€6.5m), which represents a net
profit margin of 3.5% (1.3%).
- EBITDA increased by 24.2% to €55.0m (€44.3m), corresponding to
an EBITDA margin of 9.5% (8.9%). Excluding IPO costs expensed,
EBITDA increased by 27.5% to €56.5m a margin of 9.7%.
- Number of members increased by 15.2% reaching 1,024K members at 31
December 2017 (889K). Number
of lab tests increased by 7.8% reaching 124.0m (115.0m) for
the year.
- The Board of Directors proposes that no dividend be paid for
the 2017 financial year.
With this release, Medicover also announces another investment
of €4.1m into MaxCure, which in addition to the €2.6m in January
will bring Medicover's holding to 30.5%.
|
REVENUE AND
EARNINGS
|
|
€ millions
(€m)
|
Q4
2017
|
Q4
2016
|
Growth
|
FY
2017
|
FY
2016
|
Growth
|
|
Revenue
|
152.7
|
132.5
|
15%
|
580.2
|
497.3
|
17%
|
|
Operating
profit
|
7.8
|
3.9
|
100%
|
28.8
|
17.6
|
64%
|
|
Operating profit
margin, %
|
5.1%
|
2.9%
|
|
5.0%
|
3.5%
|
|
|
Net profit
|
9.2
|
1.7
|
N/M
|
20.2
|
6.5
|
211%
|
|
Net profit margin,
%
|
6.0%
|
1.3%
|
|
3.5%
|
1.3%
|
|
|
Earnings per share,
€
|
0.067
|
0.008
|
N/M
|
0.157
|
0.046
|
241%
|
|
Diluted earnings per
share, €
|
0.067
|
0.008
|
N/M
|
0.157
|
0.045
|
249%
|
|
|
|
|
|
|
|
|
EBITDA1
|
14.6
|
11.4
|
28%
|
55.0
|
44.3
|
24%
|
|
EBITDA margin,
%1
|
9.6%
|
8.6%
|
|
9.5%
|
8.9%
|
|
|
|
|
|
|
|
|
|
[1]
For Alternative Performance Measure definitions and
reconciliations, refer to note 11
|
This information is information that Medicover AB is obliged
to make public pursuant to the EU Market Abuse Regulation and the
Securities Markets Act. The information was submitted for
publication, through the agency of the contact person set out
below, at 8.00 (CET) on 9 February
2018. This interim report and other information about
Medicover, is available at medicover.com
For further information, please contact:
Paula Treutiger, Corporate Communications & Investor
Relations,
Director
Phone: +46-73-66 6599
Mail: paula.treutiger@medicover.com
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/medicover/r/year-end-report-january-december-2017,c2449022
The following files are available for download:
|
http://mb.cision.com/Main/15662/2449022/789503.pdf
|
Year-end
report
|
